WuXi Biologics (Cayman) (FRA:1FW2) Cash-to-Debt : 1.69 (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. WuXi Biologics (Cayman)'s cash to debt ratio for the quarter that ended in Jun. 2023 was 1.69.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, WuXi Biologics (Cayman) could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for WuXi Biologics (Cayman)'s Cash-to-Debt or its related term are showing as below:

FRA:1FW2' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: 2.57 Max: No Debt
Current: 2.47

During the past 10 years, WuXi Biologics (Cayman)'s highest Cash to Debt Ratio was No Debt. The lowest was 0.11. And the median was 2.57.

FRA:1FW2's Cash-to-Debt is ranked worse than
64.85% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs FRA:1FW2: 2.47

WuXi Biologics (Cayman) Cash-to-Debt Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

WuXi Biologics (Cayman) Cash-to-Debt Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

3.08

2.55

2.59

1.97

2.47

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial													2.59	2.24	1.97	1.69	2.47

Competitive Comparison of WuXi Biologics (Cayman)'s Cash-to-Debt

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi Biologics (Cayman)'s Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Cash-to-Debt falls into.

WuXi Biologics (Cayman) Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

WuXi Biologics (Cayman)'s Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1179.959	/	(199.111	+	399.602)
	=	1.97

WuXi Biologics (Cayman)'s Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1120.564	/	(165.041	+	497.56)
	=	1.69

WuXi Biologics (Cayman) (FRA:1FW2) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

WuXi Biologics (Cayman) Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines